Delcath Systems, Inc. Sponsors Satellite Session at World Meeting of Melanoma/Skin Cancer Centers
24 November 2009 - 12:30PM
PR Newswire (US)
NEW YORK, Nov. 24 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.,
(NASDAQ:DCTH) a medical technology company testing its proprietary
treatment method for primary and metastatic cancers to the liver,
recently sponsored a Satellite Symposium at the World Meeting of
Melanoma/Skin Cancer Centers in Berlin, Germany. The session,
titled "Regional Therapeutic Options for Metastatic Melanoma," was
held on Friday, November 20 and featured updates and observations
on a variety of current therapies by clinical leaders in the field.
Dr. Jonathan S. Zager of Moffitt Cancer Center in Tampa, Florida
presented an update on the fully enrolled pivotal Phase III
Metastatic Melanoma Trial of the Delcath PHP System(TM). Dr. Zager
reviewed previously published data and outlined the Phase III
trial's demographics, methods and endpoints. The Symposium was very
well attended and generated a robust discussion among the
participating clinicians. "The World Meeting of Melanoma/Skin
Cancer Centers was an exciting opportunity to contribute to the
discussion of regional metastatic melanoma therapies with clinical
leaders from around the world," said Jason Rifkin, Delcath's Senior
Vice President, Clinical Affairs. "The robust attendance at our
Symposium suggests substantial, global anticipation for the PHP
System(TM), as clinicians worldwide look for promising therapeutic
options for hepatic disease." The Symposium also featured
presentations from Professor John Thompson of the Sydney Melanoma
Unit in Sydney, Australia; Professor Alexander M.M. Eggermont of
the Erasmus University Medical Center - Daniel den Hoed Cancer
Center in Rotterdam, The Netherlands; and Dr. H. Richard Alexander,
Jr. of the University of Maryland Marlene and Stewart Greenebaum
Cancer Center in Baltimore, Maryland. The Company announced on
October 21, 2009 that the pivotal Phase III Metastatic Melanoma
Trial met its goal of 92 patients and is fully enrolled. This
clinical study is evaluating the Delcath PHP System(TM) for the
regional delivery of melphalan to the liver to treat patients with
metastatic cutaneous and ocular melanoma who have unresectable
tumors in the liver. The Delcath PHP System(TM) is designed to
deliver significantly higher doses of anti-cancer drugs to a
patient's liver while minimizing entry of the drugs into the rest
of the patient's circulation. This isolation limits toxicities
which result from systemic chemotherapy treatments. Patients in the
Phase III trial are randomized into one of two treatment arms,
including immediate treatment with melphalan via the Delcath PHP
System(TM) or treatment with best alternative care. The study is
designed to evaluate the duration of tumor response in each of the
two study arms. Following guidelines established by U.S. Food and
Drug Administration under a Special Protocol Assessment (SPA),
patients are permitted to "cross-over" from the best alternative
care arm to receive treatment with the Delcath PHP System(TM) at
the time of disease progression. About Delcath Systems, Inc.
Delcath Systems Inc. is a medical device company specializing in
cancer treatment. The Company is testing a proprietary, patented
drug delivery system for the treatment of liver cancers. Delcath's
novel drug delivery platform is testing the delivery of ultra-high
doses of anti-cancer drugs to the liver while preventing these high
doses of drug from entering the patient's bloodstream. The Company
maintains a broad intellectual property portfolio on a worldwide
basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at
http://www.delcath.com/. The Private Securities Litigation Reform
Act of 1995 provides a safe harbor for forward-looking statements
made by the Company or on its behalf. This news release contains
forward-looking statements, which are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our
ability to successfully complete our clinical trials and secure
regulatory approval of our current or future drug-delivery system
and uncertainties regarding our ability to obtain financial and
other resources for any research, development and commercialization
activities. These factors, and others, are discussed from time to
time in our filings with the Securities and Exchange Commission.
You should not place undue reliance on these forward-looking
statements, which speak only as of the date they are made. We
undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after
the date they are made. DATASOURCE: Delcath Systems, Inc. CONTACT:
Investors, Doug Sherk or Stacey Fisher, both of EVC Group,
+1-415-896-6820; Media, Steve DiMattia of EVC Group,
+1-646-201-5445; all for Delcath Systems, Inc. Web Site:
http://www.delcath.com/
Copyright